Contact

Address: Office no 413-A, Amanora Chambers, Amanora Park Town, Hadapsar, Pune, Maharashtra, India 411028

Phone: IND : +91 9589972020 | USA : +1 6467334959 | UK : +44 2080730603

Ocugen to Participate in Upcoming May Scientific and Investor Conferences

2026-05-13T11:02:00Z

MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...

Andera Partners Leads $20 Million Series D Financing in Rivermark Medical

2026-05-13T11:00:00Z

The FloStent™ System Promises to Redefine the BPH Care Pathway

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

2026-05-13T11:00:00Z

NORWOOD, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that...

Nurix Therapeutics to Participate in Upcoming Investor Conferences

2026-05-13T11:00:00Z

BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in...

Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

2026-05-13T11:00:00Z

- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer -

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

2026-05-13T11:00:00Z

RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision...

Verano Submits DEA Registration Applications for State-Licensed Medical Cannabis Businesses Following Landmark Federal Rescheduling Order

2026-05-13T11:00:00Z

CHICAGO, May 13, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the Company has submitted...

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

2026-05-13T11:00:00Z

RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for...

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

2026-05-13T11:00:00Z

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics...

PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update

2026-05-13T11:00:00Z

Investor Webcast Scheduled for 8:00 am ET

Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

2026-05-13T11:00:00Z

WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today...

BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

2026-05-13T11:00:00Z

AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability

Seer Files Patent Infringement Lawsuit Against Nanomics

2026-05-13T11:00:00Z

Seer defends its pioneering Proteograph® Product Suite intellectual property (IP)

Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

2026-05-13T11:00:00Z

– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP –

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

2026-05-13T11:00:00Z

SAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that...

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

2026-05-13T11:00:00Z

Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership negotiations with leading oncology companies

Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year

2026-05-13T11:00:00Z

REHOVOT, Israel, and HOBOKEN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare...

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

2026-05-13T10:50:00Z

- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis -

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

2026-05-13T10:30:00Z

--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027—

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

2026-05-13T10:30:00Z

DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of...

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026

2026-05-13T10:01:00Z

- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 -

Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-05-13T10:00:00Z

– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD...

Zymeworks Announces Participation in Upcoming Investor Conferences

2026-05-13T10:00:00Z

VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel,...

NVision Expands from Quantum Sensing to Quantum Computing to Accelerate Discovery and Validation of New Therapies

2026-05-13T10:00:00Z

$55 Million Series B to Advance Quantum for Healthcare

HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026

2026-05-13T09:00:00Z

Tuebingen, Germany, May 13, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, announces that its abstract highlighting clinical data for the lead candidate darizmetinib (formerly HRX215) has been selected for a late-breaking oral presentation at the European Association for the Study...

Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors

2026-05-13T08:00:00Z

BASEL, Switzerland, May 13, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, today...

Inventiva to Present Abstracts at the EASL Congress 2026

2026-05-13T06:30:00Z

Daix (France), New York City (New York, United States), May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development...

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

2026-05-13T06:05:00Z

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver...

Fangzhou Showcases “AI+H2H” Chronic Disease Service Innovations at the National Intelligent Medicine Conference

2026-05-13T06:03:39Z

WUHAN, China, May 13, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, participated in the 2026 National Medical...

Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026

2026-05-13T06:00:00Z

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data...